TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8730606

Group type: EXPERIMENTAL
Intervention: 320 ml of red wine (providing 30 g/day of alcohol)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 30 g/day of alcohol diluted in 320 ml of clear fruit juice
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: 320 ml of dealcoholised red wine
Number of subjects: 11

Group type: COMPARATOR
Intervention: Abstinence
Number of subjects: 11
Study: 1321893

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and radiotherapy (RT) including cisplatin 100 mg/m2 on days 1 and 29, vinblastine 3 mg/m2 on days 1, 3, 29, and 31, fluorouracil (5-FU) 30 mg/kg/d by infusion on days 1 to 3 and 29 to 31, and RT of 3,000 cGy in 15 fractions.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Surgical resection following neoadjuvant treatment.
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and RT followed by additional chemotherapy and RT after surgery.
Number of subjects: 41
Study: 6463794

Group type: EXPERIMENTAL
Intervention: Minimization procedure
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 41
Study: 30591354

Group type: EXPERIMENTAL
Intervention: Abiraterone
Number of subjects: 202

Group type: COMPARATOR
Intervention: Enzalutamide
Number of subjects: 202
Study: 29884069

Group type: EXPERIMENTAL
Intervention: DIAL intervention
Number of subjects: 63

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 63
Study: 27157959

Group type: EXPERIMENTAL
Intervention: Motivational music
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Relaxation music
Number of subjects: 37

Group type: COMPARATOR
Intervention: No music
Number of subjects: 37
Study: 24766759

Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 307

Group type: EXPERIMENTAL
Intervention: Implementation challenges
Number of subjects: 307
Study: 21685369

Group type: EXPERIMENTAL
Intervention: Multistimulant home-based program, 10 home visits once per week.
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 96
Study: 21038652

Group type: COMPARATOR
Intervention: Control group treated with blood glucose (BG) and blood pressure (BP) controlling (Group A)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group with BG, BP and blood lipid (BL) controlling (Group B)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group with BG, BP, BL controlling and vitamin E administration (Group C)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Group with BG, BP, BL controlling and DSP administration (Group D)
Number of subjects: 130
Study: 17992056

Group type: EXPERIMENTAL
Intervention: Muscle strengthening exercises using a Thera Band
Number of subjects: 32

Group type: COMPARATOR
Intervention: Acupuncture therapy and physical therapy
Number of subjects: 32
Study: 15650967

Group type: EXPERIMENTAL
Intervention: Standard laparoscopy
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Histology
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Mini-laparoscopy
Number of subjects: 425
Study: 11930982

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 9649928

Group type: EXPERIMENTAL
Intervention: Indobufen
Number of subjects: 934

Group type: COMPARATOR
Intervention: Aspirin and dipyridamole
Number of subjects: 934
Study: 8547556

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 2295911

Group type: EXPERIMENTAL
Intervention: Testicular biopsy
Number of subjects: 494

Group type: EXPERIMENTAL
Intervention: Occult testicular leukemia (TL)
Number of subjects: 494

Group type: COMPARATOR
Intervention: No biopsy
Number of subjects: 494
Study: 799986

Group type: EXPERIMENTAL
Intervention: Tofranil 25 mg three times daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study: 30284349

Group type: EXPERIMENTAL
Intervention: Oral semaglutide (up to 14 mg)
Number of subjects: 3183

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3183
Study: 28521380

Group type: EXPERIMENTAL
Intervention: PAT student tutor
Number of subjects: 94

Group type: COMPARATOR
Intervention: University professor
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Overall evaluation
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Interrater reliability
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Point difference
Number of subjects: 94
Study: 26113111

Group type: EXPERIMENTAL
Intervention: Oxidized zirconium femoral head with UHMWPE
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stainless steel femoral head with UHMWPE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Oxidized zirconium femoral head with HXLPE
Number of subjects: 100

Group type: COMPARATOR
Intervention: Stainless steel femoral head with HXLPE
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups (Oxidized zirconium and Stainless steel)
Number of subjects: 100
Study: 22492785

Group type: EXPERIMENTAL
Intervention: Educational intervention on low-sodium diet
Number of subjects: 52

Group type: COMPARATOR
Intervention: Usual care (no dietary instructions)
Number of subjects: 52
Study: 20684664

Group type: EXPERIMENTAL
Intervention: DHEP/heparin plaster
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: DHEP plaster
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo plaster
Number of subjects: 185
Study: 18463399

Group type: EXPERIMENTAL
Intervention: Case management intervention group (n = 344)
Number of subjects: 683

Group type: COMPARATOR
Intervention: Case management control group (n = 339)
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Participants with chronic bronchitis
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Participants with a relative with cancer
Number of subjects: 683
Study: 15941146

Group type: EXPERIMENTAL
Intervention: Nebivolol (1.25 to 5 mg per day)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Betalok ZOK (12.5 to 100 mg per day)
Number of subjects: 40
Study: 12817904

Group type: EXPERIMENTAL
Intervention: 600 mg lithium
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Hypertonic saline infusion
Number of subjects: 23
Study: 10423106

Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 0
Study: 8947069

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (1,000 microg)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 2017225

Group type: EXPERIMENTAL
Intervention: Antilymphocyte globulin, methylprednisolone, and cyclosporine
Number of subjects: 84

Group type: COMPARATOR
Intervention: Antilymphocyte globulin and methylprednisolone
Number of subjects: 84
Study: 6812750

Group type: EXPERIMENTAL
Intervention: Ketanserin 10 mg intravenously
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo (saline 9 g/l)
Number of subjects: 9
Study: 30118528

Group type: EXPERIMENTAL
Intervention: Platform-switching implant (PS)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Platform-switching implant and bone graft (BG/PS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-platform-switching implant (Non-PS)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Non-platform-switching implant and bone graft (BG/Non-PS)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Platform-switching implant (PS) and bone graft (BG/PS)
Number of subjects: 56
Study: 27614801

Group type: EXPERIMENTAL
Intervention: 4 g/d omega-3 fatty acid supplementation
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no omega-3 fatty acid supplementation)
Number of subjects: 20
Study: 24930475

Group type: EXPERIMENTAL
Intervention: Primary intra‐ocular lens (IOL) implantation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Press‐on spherical lens
Number of subjects: 60
Study: 23162960

Group type: EXPERIMENTAL
Intervention: Lateral Tibial Tunnel (LTT)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Classic Anteromedial Tibial Tunnel (MTT)
Number of subjects: 20
Study: 21143400

Group type: EXPERIMENTAL
Intervention: CO₂ GAP ≥10
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: CO₂ GAP
Number of subjects: 412

Group type: COMPARATOR
Intervention: Arterial‐alveolar gradient
Number of subjects: 412
Study: 17418112

Group type: EXPERIMENTAL
Intervention: Familiar solution (non-optimal solution)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Expert knowledge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Einstellung (set) effect paradigm
Number of subjects: 0
Study: 15866569

Group type: EXPERIMENTAL
Intervention: GnRH agonist (600 microg of busereline acetate per day starting in the midluteal phase of the cycle)
Number of subjects: 65

Group type: COMPARATOR
Intervention: GnRH antagonist (0.25 mg/d of Cetrorelix starting from day 6 of the cycle)
Number of subjects: 65
Study: 12700623

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (increased consumption of fish, fruit, raw and cooked vegetables, and olive oil)
Number of subjects: 11323

Group type: COMPARATOR
Intervention: Control group (worst dietary score quarter)
Number of subjects: 11323
Study: 10896253

Group type: EXPERIMENTAL
Intervention: Transdermal hormone replacement therapy (HRT)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 98
Study: 8727840

Group type: EXPERIMENTAL
Intervention: Perceived impact of child's chronic illness
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Need to watch for changes in child's condition
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Presence of communication or speech problems
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Number of hospitalizations in the previous year
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Condition parameters and service use
Number of subjects: 169
Study: 1907128

Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT), 45 Gy in 25 fractions (plus a perineal boost of 5 Gy in 2 fractions after abdomino-perineal resection)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No further treatment (NO RT)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Pelvic radiotherapy (RT)
Number of subjects: 70
Study: 6340504

Group type: EXPERIMENTAL
Intervention: Gentamicin via the McHenry method
Number of subjects: 317

Group type: COMPARATOR
Intervention: Tobramycin via the McHenry method
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Gentamicin via the Sawchuk/Zaske method
Number of subjects: 317

Group type: COMPARATOR
Intervention: Tobramycin via the Sawchuk/Zaske method
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Elevated trough serum aminoglycoside concentrations
Number of subjects: 317

Group type: COMPARATOR
Intervention: Nonelevated trough serum aminoglycoside concentrations
Number of subjects: 317
Study: 31210076

Group type: EXPERIMENTAL
Intervention: Gain-framed video
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Loss-framed video
Number of subjects: 133
Study: 29898902

Group type: EXPERIMENTAL
Intervention: Liraglutide (≤1.8 mg daily)
Number of subjects: 9360

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9360

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9360
Study: 26429360

Group type: EXPERIMENTAL
Intervention: High-dose dexmedetomidine (loading dose, 1 μg/kg; maintenance dose, 0.6 μg/kg/h)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Low-dose dexmedetomidine (loading dose, 0.6 μg/kg; maintenance dose, 0.3 μg/kg/h)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control group (0.9% saline as placebo)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: High-dose dexmedetomidine
Number of subjects: 116
Study: 24477765

Group type: COMPARATOR
Intervention: Visual targets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Touch targets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Anticipation errors
Number of subjects: 20
Study: 22870700

Group type: EXPERIMENTAL
Intervention: Propranolol with 1064 nm Nd:YAG laser (A group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: 1064 nm Nd:YAG laser (B group)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Propranolol (C group)
Number of subjects: 97
Study: 20701511

Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 38

Group type: COMPARATOR
Intervention: Sedation
Number of subjects: 38
Study: 17334829

Group type: EXPERIMENTAL
Intervention: IRT based scale combining MHAQ and PF10
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: MHAQ
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: PF10
Number of subjects: 339

Group type: EXPERIMENTAL
Intervention: MHAQ and PF10
Number of subjects: 339
Study: 15606570

Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide 100 microg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 12744870

Group type: EXPERIMENTAL
Intervention: CF‐BS‐ETEC vaccine
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo (E. coli K12)
Number of subjects: 158
Study: 10471225

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 7755164

Group type: EXPERIMENTAL
Intervention: β-lactam/β-lactamase inhibitor agents (ampicillin/sulbactam, ticarcillin/clavulanate, piperacillin/tazobactam)
Number of subjects: 0

Group type: COMPARATOR
Intervention: piperacillin/tazobactam
Number of subjects: 0

Group type: COMPARATOR
Intervention: aminoglycoside plus antianaerobic therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: second-generation cephalosporin or aminoglycoside plus antianaerobic comparators
Number of subjects: 0
Study: 1852084

Group type: EXPERIMENTAL
Intervention: RIT 4237 bovine rotavirus vaccine
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 7017311

Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional antibiotic therapy
Number of subjects: 0
Study: 31535299

Group type: EXPERIMENTAL
Intervention: Surgery for regional lymph nodes (Selective Lymphadenectomy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nodal intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MSLT-I, MSLT-II, DeCOG trials
Number of subjects: 0
Study: 30984985

Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) deep brain stimulation (DBS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Globus pallidus interna (GPi) deep brain stimulation (DBS)
Number of subjects: 12
Study: 28336345

Group type: EXPERIMENTAL
Intervention: Irish set dance classes (1.5 hours/week for 10 weeks + home dance program 20 minutes, 3 times/week)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study: 27264413

Group type: EXPERIMENTAL
Intervention: 20 mg/day atorvastatin
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 4 mg/day pitavastatin
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 10 mg/day pravastatin
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 30 mg/day fluvastatin
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin therapy
Number of subjects: 118

Group type: COMPARATOR
Intervention: Low-intensity statin therapy
Number of subjects: 118
Study: 24754318

Group type: EXPERIMENTAL
Intervention: VNS + BMP
Number of subjects: 112

Group type: COMPARATOR
Intervention: BMP
Number of subjects: 112
Study: 23012427

Group type: EXPERIMENTAL
Intervention: Ketamine (NMDA receptor antagonist)
Number of subjects: 0
Study: 19442931

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg, oral, 90 min)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 18161398

Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice a day)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 63
Study: 14693528

Group type: EXPERIMENTAL
Intervention: GW433908 1,395 mg BID
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: GW433908 1,860 mg BID
Number of subjects: 78

Group type: COMPARATOR
Intervention: Amprenavir 1,200 mg BID
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: All three regimens (GW433908 and amprenavir)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: GW433908 groups
Number of subjects: 78
Study: 12512665

Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Number of subjects: 681

Group type: COMPARATOR
Intervention: Prilocaine plain
Number of subjects: 681
Study: 9835204

Group type: EXPERIMENTAL
Intervention: Takayasu's arteritis patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Other vascular diseases (control)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Autoimmune diseases (control)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal healthy individuals (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Collagenase treatment of aorta
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Takayasu's arteritis patients' sera
Number of subjects: 30
Study: 8120290

Group type: EXPERIMENTAL
Intervention: 1987‐88 NFCS 24‐hour recall procedures
Number of subjects: 697

Group type: COMPARATOR
Intervention: 1977‐78 NFCS 24‐hour recall procedures
Number of subjects: 697
Study: 2553325

Group type: COMPARATOR
Intervention: Carbidopa
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor infusion
Number of subjects: 10
Study: 776194

Group type: EXPERIMENTAL
Intervention: Aptocaine 1%, 2%, 3%
Number of subjects: 55

Group type: COMPARATOR
Intervention: Lignocaine 2%
Number of subjects: 55

Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Mepivacaine 1%, 2%, 3%
Number of subjects: 55

Group type: COMPARATOR
Intervention: Prilocaine 1%, 2%, 3%
Number of subjects: 55
Study: 30654328

Group type: EXPERIMENTAL
Intervention: Behaviourally enhanced messages via smartphone application
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (usual DAQI messages)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Behaviourally enhanced messages
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both message formats (behaviourally enhanced and usual DAQI messages)
Number of subjects: 82
Study: 28304211

Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: BONE+EMD
Number of subjects: 39

Group type: COMPARATOR
Intervention: BONE
Number of subjects: 39
Study: 25414266

Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 379

Group type: COMPARATOR
Intervention: Amphotericin B (AmB)
Number of subjects: 379
Study: 23506973

Group type: EXPERIMENTAL
Intervention: Peer companionship intervention for older adults
Number of subjects: 0
Study: 21444874

Group type: EXPERIMENTAL
Intervention: MRI screening
Number of subjects: 1275

Group type: COMPARATOR
Intervention: Comparison group (conventional screening)
Number of subjects: 1275
Study: 19801069

Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 13
Study: 16688374

Group type: EXPERIMENTAL
Intervention: Acne Dressing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Skin tapes
Number of subjects: 20
Study: 15358983

Group type: EXPERIMENTAL
Intervention: 300 mg L-dopa
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: 1.25 mg bromocriptine
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 11399369

Group type: EXPERIMENTAL
Intervention: iodixanol 270 mg I/ml
Number of subjects: 111

Group type: COMPARATOR
Intervention: iohexol 300 mg I/ml
Number of subjects: 111
Study: 7902901

Group type: EXPERIMENTAL
Intervention: Selective episiotomy (limited to specified maternal or fetal indications)
Number of subjects: 2606

Group type: COMPARATOR
Intervention: Routine episiotomy (following the hospital's previous policy)
Number of subjects: 2606

Group type: EXPERIMENTAL
Intervention: Selective episiotomy
Number of subjects: 2606
Study: 2824706

Group type: EXPERIMENTAL
Intervention: Cisplatin (200 mg/m2 divided in five daily doses) and vinblastine (7.5 mg/m2 as a continuous IV infusion over five days) followed by radiation therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cisplatin and vinblastine followed by observation only (no radiation)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cisplatin and vinblastine followed by radiation therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Cisplatin and vinblastine followed by observation only (no radiation) for responders
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Cisplatin and vinblastine followed by radiation therapy for nonresponders
Number of subjects: 47
Study: 30990213

Group type: EXPERIMENTAL
Intervention: Bread fortified with 2.3 g PS and 228 mg CC (PS-C)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Bread fortified with placebo (PL) and curcumin (CC) (PL-C)
Number of subjects: 75
Study: 28847641

Group type: EXPERIMENTAL
Intervention: SD OCT-based risk assessment model for new onset of CP-visible GA
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: SD OCT-based risk assessment model for central GA
Number of subjects: 317
Study: 26867333

Group type: EXPERIMENTAL
Intervention: Fennel tea (5 grams of dried fennel fruit in 130 mL boiled water, twice per day)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (equal quantity of water, twice per day)
Number of subjects: 159
Study: 23196419

Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 10

Group type: COMPARATOR
Intervention: PSV30
Number of subjects: 10

Group type: COMPARATOR
Intervention: PSV1
Number of subjects: 10
Study: 21710343

Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (N-ACC) 2 × 1200 mg/d for 48 h with optimal hydration
Number of subjects: 251

Group type: COMPARATOR
Intervention: Placebo plus optimal hydration
Number of subjects: 251

Group type: EXPERIMENTAL
Intervention: N-ACC and placebo groups
Number of subjects: 251
Study: 18473689

Group type: EXPERIMENTAL
Intervention: Cell phone‐based diabetes management software (WellDoc Communications, Inc.)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 30
Study: 16524858

Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no LT4 therapy)
Number of subjects: 33
Study: 15631797

Group type: EXPERIMENTAL
Intervention: Cefdinir 100 mg, orally, three times a day for 7-14 days
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cefaclor 500 mg, orally, three times a day for 7-14 days
Number of subjects: 64